

Join us in seeing the future of MR



Kelly Londy
President & CEO, Global MR

—
GE HealthCare,
Waukesha, WI

As we look toward the future, we are excited to advance in our mission of defining what MR technology can become in the coming years. Yet, we also acknowledge the challenges that lie ahead of us in this journey.

It's no secret that healthcare equity is a growing, pressing challenge. With an aging population worldwide, the disease burden is rising and increasing the need for MR procedures in an already stretched area of healthcare.

At ISMRM 2024 in Singapore, we launched our SIGNA™ Vision – an open invitation for you to join us in seeing the future of MR and help us change the outcome; and a commitment to continue to develop innovative MR technology that is accurate, accessible, and provides you with the actionable insights you need to address these growing challenges.


Today, we're proud to both reaffirm this commitment and reflect on some of the milestones that take us one step closer to delivering on this vision.

As leaders in AI and digital solutions, we have continued to evolve our AI-enabled tools to help standardize clinical excellence and optimize efficiency over the past 12 months. At RSNA 2024 we announced the expansion of Sonic DL™ to 3D imaging*, a significant stride in delivering on our promise of Effortless Imaging.

In October 2024, we received FDA clearance for SIGNA MAGNUS†, our premium, head-only MR scanner dedicated to brain exploration. This powerful device is designed to deliver the next neurological breakthroughs and pave the way for new treatments for some of the most debilitating and burdening diseases.

Our portfolio and innovations are built on the concept of broadening access to MR and pushing the boundaries of MR sustainability – both in an environmental and operational context. This exact concept has been the driving force behind Freelenium‡ – our sealed magnet technology, unveiled at the European Congress of Radiology (ECR) in Vienna in February of this year.

Freelenium is built upon our already proven and trusted lightweight magnet technology, and is designed to deliver a responsible, future-facing sealed magnet technology that prioritizes helium independence, operational security and energy efficiency alike.

As medtech pioneers, we're always on a mission to push the boundaries of what MR can be. These recent milestones reflect GE HealthCare's determination to stay on the edge of innovation, with a relentless focus on delivering medical technology that is effortless, sustainable and groundbreaking. I hope you will leave this year's ISMRM inspired by the power to explore further and the accomplishments we should look forward to achieving together. 

* Sonic DL for 3D is 510(k) pending at the US FDA. Not yet CE Marked. Not available for sale in all regions.

† SIGNA™ MAGNUS is 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions.

‡ Technology in development that represents ongoing research and development efforts. Not for sale. Not CE marked. Not cleared or approved by the US FDA or any other global regulator for commercial availability.